Reporting potential conflicts of interest by Spahn, Donat R
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Reporting potential conflicts of interest
Spahn, Donat R
DOI: https://doi.org/10.1016/j.bjane.2014.09.008
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-128883
Published Version
 
 
Originally published at:
Spahn, Donat R (2016). Reporting potential conflicts of interest. Brazilian Journal of Anesthesiology
(English Edition), 66(2):222-223.
DOI: https://doi.org/10.1016/j.bjane.2014.09.008
Rev Bras Anestesiol. 2016;66(2):222--223
REVISTA
BRASILEIRA  DE
ANESTESIOLOGIA Ofﬁcial  Publication  of  the  Brazilian  Society  of  Anesthesiologywww.sba.com.br
LETTER TO THE EDITOR
Reporting potential conﬂicts of
interest
Comunicando potenciais conﬂitos de interesse
Dear  Editor,
It  was  with  surprise  that  I  saw  recently  the  paper  of  Sadeghi
et  al.1 published  in  your  journal  with  me  as  a  co-author.  As
a  matter  of  fact,  I  was  involved  in  the  study  design,  data
analysis  and  writing  of  the  manuscript.  However,  I  was  not
involved  in  the  submission  process  of  the  manuscript  to  your
journal  which  explains  why  my  conﬂict  of  interest  statement
is  lacking  in  the  current  publication.  This  is  highly  unfortu-
nate  since  openly  declaring  all  potential  conﬂicts  of  interest
are  of  prime  importance  to  me.  I  therefore  declare  in  this
letter  all  my  conﬂicts  of  interests.
Dr.  Spahn’s  academic  department  is  receiving  grant
support  from  the  Swiss  National  Science  Foundation,
Berne,  Switzerland  (grant  numbers:  100  014  138545/1,
33CM30 124117,  33CM30  140339  and  406440-131268),  the
Ministry  of  Health  (Gesundheitsdirektion)  of  the  Canton  of
Zurich,  Switzerland  for  Highly  Specialized  Medicine,  the
Swiss  Society  of  Anesthesiology  and  Reanimation  (SGAR),
Berne,  Switzerland  (no  grant  numbers  attributed),  the
Swiss  Foundation  for  Anesthesia  Research,  Zurich,  Switzer-
land  (no  grant  numbers  attributed),  Bundesprogramm
Chancengleichheit,  Berne,  Switzerland  (no  grant  numbers
attributed),  CSL  Behring,  Berne,  Switzerland  (no  grant  num-
bers  attributed),  Vifor  SA,  Villars-sur-Glâne,  Switzerland  (no
grant  numbers  attributed).
Dr.  Spahn  was  the  chairman  of  the  ABC  Faculty  and  is
the  co-chairman  of  the  ABC-Trauma  Faculty,  which  both
are  managed  by  Physicians  World  Europe  GmbH,  Mannheim,
Germany  and  sponsored  by  unrestricted  educational  grants
from  Novo  Nordisk  Health  Care  AG,  Zurich,  Switzerland,  CSL
Behring  GmbH,  Marburg,  Germany  and  LFB  Biomédicaments,
Courtaboeuf  Cedex,  France.
DOI of original article: http://dx.doi.org/10.1016/j.bjane.2013.10.010
In  the  past  5  years,  Dr.  Spahn  has  received  hono-
raria  or  travel  support  for  consulting  or  lecturing  from
the  following  companies:  Abbott  AG,  Baar,  Switzerland,
AMGEN  GmbH,  Munich,  Germany,  AstraZeneca  AG,  Zug,
Switzerland,  Bayer  (Schweiz)  AG,  Zürich,  Switzerland,  Bax-
ter  AG,  Volketswil,  Switzerland,  Baxter  S.p.A.,  Roma,  Italy,
B.  Braun  Melsungen  AG,  Melsungen,  Germany,  Boehringer
Ingelheim  (Schweiz)  GmbH,  Basel,  Switzerland,  Bristol-
Myers-Squibb,  Rueil-Malmaison  Cedex,  France  and  Baar,
Switzerland,  CSL  Behring  GmbH,  Hattersheim  am  Main,
Germany  and  Berne,  Switzerland,Curacyte  AG,  Munich,  Ger-
many,  Ethicon  Biosurgery,  Sommerville,  New  Jersey,  USA,
Fresenius  SE,  Bad  Homburg  v.d.H.,  Germany,  Galenica  AG,
Bern,  Switzerland  (including  Vifor  SA,  Villars-sur-Glâne,
Switzerland),GlaxoSmithKline  GmbH  &  Co.  KG,  Hamburg,
Germany,  Janssen-Cilag  AG,  Baar,  Switzerland,  Janssen-
Cilag  EMEA,  Beerse,  Belgium,  Merck  Sharp  &  Dohme  AG,
Luzern,  Switzerland,  Novo  Nordisk  A/S,  Bagsvärd,  Den-
mark,  Octapharma  AG,  Lachen,  Switzerland,  Organon  AG,
Pfäfﬁkon/SZ,  Switzerland,  Oxygen  Biotherapeutics,  Costa
Mesa,  CA,  Photonics  Healthcare  GmbH,  Munich,  Germany,
ratiopharm  Arzneimittel  Vertriebs-GmbH,  Vienna,  Austria,
Roche  Diagnostics  International  Ltd,  Reinach,  Switzer-
land,  Roche  Pharma  (Schweiz)  AG,  Reinach,  Switzerland,
Schering-Plough  International,  Inc.,  Kenilworth,  New  Jer-
sey,  USA,  Tem  International  GmbH,  Munich,  Germany,  Verum
Diagnostica  GmbH,  Munich,  Germany,  Vifor  Pharma  Deutsch-
land  GmbH,  Munich,  Germany,  Vifor  Pharma  Österreich
GmbH,  Vienna,  Austria,  Vifor  (International)  AG,  St.  Gallen,
Switzerland.
The  only  relationship  with  the  research  presented  in  the
paper  of  Sadeghi  et  al.1 may  be  the  fact  that  I  met  the
senior  author  of  the  paper,  Doctor  Ali  Movafegh,  at  a  CSL
Behring  sponsored  educational  event  and  that  CSL  Behring
is  the  manufacturer  of  the  ﬁbrinogen  used  in  this  study.  How-
ever,  CSL  Behring  had  no  involvement  in  this  study  and  the
ﬁbrinogen  used  in  the  study  was  regularly  purchased  by  the
Tehran  University  of  Medical  Sciences.
http://dx.doi.org/10.1016/j.bjane.2014.09.008
0104-0014/© 2015 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved.
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The  author  declares  no  conﬂicts  of  interest.
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